



Galleri® multi-cancer early detection test for Gates

A \$949 value — available to you at no cost as a covered benefit.

What is the Galleri test?

Galleri is a blood test that can detect 50+ cancer types and can be taken annually.^{1,2}

Why take the Galleri test?

Nearly 70% of cancers have no recommended screenings available^{2,3} and are found accidentally or when symptoms appear.^{4,5} By then, the cancer is often in late stages when outcomes may be poor, and treatment options may be limited.^{4,5}

The Galleri test can increase your chance of finding cancer early when used in addition to recommended single-cancer screenings.^{2,6,7} This may give you and your doctor more time to take action.

How does Galleri testing work?



Request your test at Galleri.com/Gates

An independent telemedicine provider reviews your request.



Get your kit

If approved, you'll receive a collection kit in the mail.



Schedule your blood draw

Get your blood drawn at home, work, or a local partner lab.



Learn your result

Sent to you and your telemedicine provider within 2-3 weeks.

The Galleri test is available by prescription only. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.



Request your Galleri test

Scan the QR code or visit Galleri.com/Gates

One result, two possibilities:

No Cancer Signal Detected (NCSD)

About 99% of people will get this result.⁶

Proactive care: Continue your other recommended screenings and consider taking the Galleri test annually. Galleri detects a signal associated with existing cancer in the body.¹ The NCSD result does not predict whether you will develop cancer in the future.¹

Cancer Signal Detected + Cancer Signal Origin

Around 1% of people, age 50-79, will get this result.⁶ The cancer rate is lower in people under the age of 50.⁸

Evaluation for cancer: The Galleri test predicts the tissue type or organ associated with the cancer signal to help guide the next steps. Diagnostic evaluation is needed to confirm cancer.

Am I eligible? The Galleri test is available annually, at no cost, to eligible Gates employees and their dependents aged 40-49 with risk factors and 50 years old or older.

Your Galleri test result and medical information are confidential and will not be shared with your employer.



Request your Galleri test

Scan the QR code or visit Galleri.com/Gates

Important Safety Information

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. **Rx only.**

Laboratory/Test Information

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes. testing. The Galleri test is intended for clinical purposes.

References: **1.** Klein EA, et al. *Ann Oncol.* 2021;32(9):1167-77. **2.** US Preventive Services Task Force. A,B,C grade recommendations, cancer, screenings [cited 2023 Oct 23]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results **3.** American Cancer Society. Cancer facts & figures 2022. <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html> [GRAIL, Inc. Data on file: GA-2021-0065] **4.** American Cancer Society. Early detection. The cancer atlas. <https://canceratlas.cancer.org/taking-action/early-detection/> **5.** Etzioni R, et al. *Nat Rev Cancer.* 2003;3(4):243-52. **6.** Schrag D, et al. *Lancet.* 2023;402:1251-1260. **7.** Hackshaw A, et al. *Br J Cancer.* 2021;125(10):1432-42. **8.** SEER*Stat Database Incidence - SEER Research Limited-Field Data, 21 Regs, Nov 2020 Sub (2000-2018) - Surveillance Research Program, released Apr 2021, based on the Nov 2020 submission. Risk Factor. [GRAIL, Inc. Data on file GR-2021-0067].